Open AccessRisk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy
Author(s) -
ChihWen Wang,
WanLong Chuang,
Hung-Che Chiang,
Po-Chin Huang,
MingLung Yu,
ChiaYen Dai
Publication year - 2020
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.535
H-Index - 42
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000312
Subject(s) - medicine , heroin , hepatitis c , hepatitis c virus , odds ratio , opiate substitution treatment , opioid , drug , virology , immunology , virus , pharmacology , receptor , buprenorphine
Hepatitis C virus (HCV) is the most common viral infection among illicit drug users in the world. Although intervention of needle and syringe program and opioid substitution therapy had engaged to prevent HCV infection, the prevalence of HCV infection does not seem to decline. The aim of this study was to estimate the risk of HCV infection in injecting drug users (IDUs) and noninjecting drug users (NIDUs) receiving opioid substitution therapy.